{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:05:12Z","timestamp":1793837112644,"version":"4.6.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81701741"],"award-info":[{"award-number":["81701741"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In order to study the CXCR4 expression with [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]pentixafor PET in different types of non-Hodgkin lymphoma, we performed a retrospective study to describe the [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]pentixafor PET\/CT imaging in a spectrum of lymphomas and to compare it with [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-seven patients with newly diagnosed non-Hodgkin lymphoma were recruited retrospectively. [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]pentixafor PET showed increased radioactivity in lymphoplasmacytic lymphoma (\n                      <jats:italic>n<\/jats:italic>\n                      = 8), marginal zone lymphoma (\n                      <jats:italic>n<\/jats:italic>\n                      = 4), diffuse large B cell lymphoma (\n                      <jats:italic>n<\/jats:italic>\n                      = 3), follicular lymphoma (\n                      <jats:italic>n<\/jats:italic>\n                      = 2), mantle cell lymphoma (\n                      <jats:italic>n<\/jats:italic>\n                      = 1), unclassified indolent B cell lymphoma (\n                      <jats:italic>n<\/jats:italic>\n                      = 3), and enteropathy associated T cell lymphoma (\n                      <jats:italic>n<\/jats:italic>\n                      = 3). However, peripheral T cell lymphoma, not otherwise specified (\n                      <jats:italic>n<\/jats:italic>\n                      = 1), and NK\/T cell lymphoma (\n                      <jats:italic>n<\/jats:italic>\n                      = 2) were not avid for [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]pentixafor. In comparison to [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET, [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]pentixafor PET demonstrated more extensive disease and higher radioactivity in lymphoplasmacytic lymphoma and marginal zone lymphoma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      CXCR4 expression varies in different types of non-Hodgkin lymphoma. Overexpression of CXCR4 was detected with [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]pentixafor PET\/CT in lymphoplasmacytic lymphoma, marginal zone lymphoma, diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, unclassified indolent B cell lymphoma, and enteropathy associated T cell lymphoma. The uptake of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]pentixafor was higher than [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG in lymphoplasmacytic lymphoma and marginal zone lymphoma.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-020-00681-7","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T05:03:02Z","timestamp":1596603782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Preliminary evidence of imaging of chemokine receptor-4-targeted PET\/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG"],"prefix":"10.1186","volume":"10","author":[{"given":"Qingqing","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5787-1136","authenticated-orcid":false,"given":"Yaping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"681_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15252\/emmm.201404698","volume":"7","author":"K Philipp-Abbrederis","year":"2015","unstructured":"Philipp-Abbrederis K, Herrmann K, Knop S, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7:477\u201387.","journal-title":"EMBO Mol Med"},{"key":"681_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","volume":"49","author":"UM Domanska","year":"2013","unstructured":"Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4\/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49:219\u201330.","journal-title":"Eur J Cancer"},{"key":"681_CR3","doi-asserted-by":"publisher","first-page":"77\u2009s","DOI":"10.2967\/jnumed.116.186874","volume":"58","author":"AME Walenkamp","year":"2017","unstructured":"Walenkamp AME, Lapa C, Herrmann K, et al. CXCR4 ligands: the next big hit? J Nucl Med. 2017;58:77\u2009s\u201382\u2009s.","journal-title":"J Nucl Med"},{"key":"681_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.7150\/thno.11251","volume":"5","author":"HJ Wester","year":"2015","unstructured":"Wester HJ, Keller U, Schottelius M, et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics. 2015;5:618\u201330.","journal-title":"Theranostics."},{"key":"681_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7150\/thno.16576","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Schreder M, Schirbel A, et al. [68Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [18F]FDG and laboratory values. Theranostics. 2017;7:205\u201312.","journal-title":"Theranostics."},{"key":"681_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/RLU.0000000000002067","volume":"43","author":"Q Pan","year":"2018","unstructured":"Pan Q, Luo Y, Cao X, et al. Multiple myeloma presenting as a superscan on 68Ga-Pentixafor PET\/CT. Clin Nucl Med. 2018;43:462\u20133.","journal-title":"Clin Nucl Med"},{"key":"681_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","volume":"47","author":"Q Pan","year":"2020","unstructured":"Pan Q, Cao X, Luo Y, et al. Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2020;47:537\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"681_CR8","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2967\/jnumed.119.226134","volume":"60","author":"Y Luo","year":"2019","unstructured":"Luo Y, Cao X, Pan Q, et al. (68)Ga-Pentixafor PET\/CT for imaging of chemokine receptor 4 expression in Waldenstrom macroglobulinemia\/lymphoplasmacytic lymphoma: comparison to (18)F-FDG PET\/CT. J Nucl Med. 2019;60:1724\u20139.","journal-title":"J Nucl Med"},{"key":"681_CR9","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/RLU.0000000000002131","volume":"43","author":"Y Luo","year":"2018","unstructured":"Luo Y, Pan Q, Feng J, et al. Chemokine receptor CXCR4-targeted PET\/CT with 68Ga-Pentixafor shows superiority to 18F-FDG in a patient with Waldenstrom macroglobulinemia. Clin Nucl Med. 2018;43:548\u201350.","journal-title":"Clin Nucl Med"},{"key":"681_CR10","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.7150\/thno.31032","volume":"9","author":"AR Haug","year":"2019","unstructured":"Haug AR, Leisser A, Wadsak W, et al. Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-Pentixafor-PET\/MRI. Theranostics. 2019;9:3653\u20138.","journal-title":"Theranostics."},{"key":"681_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/RLI.0000000000000469","volume":"53","author":"ME Mayerhoefer","year":"2018","unstructured":"Mayerhoefer ME, Jaeger U, Staber P, et al. [68Ga]Ga-Pentixafor PET\/MRI for CXCR4 imaging of chronic lymphocytic leukemia: preliminary results. Investig Radiol. 2018;53:403\u20138.","journal-title":"Investig Radiol"},{"key":"681_CR12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3324\/haematol.2016.142976","volume":"101","author":"P Herhaus","year":"2016","unstructured":"Herhaus P, Habringer S, Philipp-Abbrederis K, et al. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. Haematologica. 2016;101:932\u201340.","journal-title":"Haematologica."},{"key":"681_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7150\/thno.21397","volume":"8","author":"S Habringer","year":"2018","unstructured":"Habringer S, Lapa C, Herhaus P, et al. Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics. Theranostics. 2018;8:369\u201383.","journal-title":"Theranostics."},{"key":"681_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2967\/jnumed.115.167361","volume":"57","author":"K Herrmann","year":"2016","unstructured":"Herrmann K, Schottelius M, Lapa C, et al. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled Pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med. 2016;57:248\u201351.","journal-title":"J Nucl Med"},{"key":"681_CR15","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.7150\/thno.19050","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Herrmann K, Schirbel A, et al. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics. 2017;7:1589\u201397.","journal-title":"Theranostics."},{"key":"681_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2967\/jnumed.118.210997","volume":"60","author":"C Lapa","year":"2019","unstructured":"Lapa C, Hanscheid H, Kircher M, et al. Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma. J Nucl Med. 2019;60:60\u20134.","journal-title":"J Nucl Med"},{"key":"681_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/ajh.22044","volume":"86","author":"R Banwait","year":"2011","unstructured":"Banwait R, O'Regan K, Campigotto F, et al. The role of 18F-FDG PET\/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol. 2011;86:567\u201372.","journal-title":"Am J Hematol"},{"key":"681_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"681_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1182\/blood-2007-12-129395","volume":"112","author":"HT Ngo","year":"2008","unstructured":"Ngo HT, Leleu X, Lee J, et al. SDF-1\/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood. 2008;112:150\u20138.","journal-title":"Blood."},{"key":"681_CR20","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1080\/10428194.2017.1298754","volume":"58","author":"D Albano","year":"2017","unstructured":"Albano D, Bosio G, Giubbini R, et al. 18F-FDG PET\/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation. Leukemia & lymphoma. 2017;58:2328\u201334.","journal-title":"Leukemia & lymphoma"},{"key":"681_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.clml.2019.10.006","volume":"20","author":"D Albano","year":"2020","unstructured":"Albano D, Durmo R, Treglia G, et al. (18)F-FDG PET\/CT or PET role in MALT lymphoma: an open issue not yet solved-a critical review. Clinical lymphoma, myeloma & leukemia. 2020;20:137\u201346.","journal-title":"Clinical lymphoma, myeloma & leukemia"},{"key":"681_CR22","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00432-016-2220-6","volume":"142","author":"S Stollberg","year":"2016","unstructured":"Stollberg S, Kammerer D, Neubauer E, et al. Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin. J Cancer Res Clin Oncol. 2016;142:2239\u201347.","journal-title":"J Cancer Res Clin Oncol"},{"key":"681_CR23","first-page":"614","volume":"60","author":"O Viering","year":"2019","unstructured":"Viering O, Kircher M, Lapa C, et al. [68Ga]Pentixafor PET\/CT is superior to [18F]FDG PET\/CT in newly diagnosed marginal zone lymphoma. J Nucl Med. 2019;60:614.","journal-title":"J Nucl Med"},{"key":"681_CR24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/sj.leu.2402107","volume":"15","author":"J Durig","year":"2001","unstructured":"Durig J, Schmucker U, Duhrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia. 2001;15:752\u20136.","journal-title":"Leukemia."},{"key":"681_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-015-0004-3","volume":"4","author":"S Middle","year":"2015","unstructured":"Middle S, Coupland SE, Taktak A, et al. Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Exp Hematol Oncol. 2015;4:10.","journal-title":"Exp Hematol Oncol"},{"key":"681_CR26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/RLU.0000000000002923","volume":"45","author":"Q Pan","year":"2020","unstructured":"Pan Q, Luo Y, Cao X, et al. Posttreated POEMS syndrome with concurrent follicular lymphoma revealed by 18F-FDG and 68Ga-Pentixafor PET\/CT. Clin Nucl Med. 2020;45:220\u20132.","journal-title":"Clin Nucl Med"},{"key":"681_CR27","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.3390\/cancers11121831","volume":"11","author":"D Albano","year":"2019","unstructured":"Albano D, Laudicella R, Ferro P, et al. The role of 18F-FDG PET\/CT in staging and prognostication of mantle cell lymphoma: an Italian multicentric study. Cancers (Basel). 2019;11:1831.","journal-title":"Cancers (Basel)"},{"key":"681_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.clml.2020.01.018","volume":"20","author":"D Albano","year":"2020","unstructured":"Albano D, Treglia G, Gazzilli M, et al. (18)F-FDG PET or PET\/CT in mantle cell lymphoma. Clinical lymphoma, myeloma & leukemia. 2020;20:422\u201330.","journal-title":"Clinical lymphoma, myeloma & leukemia"},{"key":"681_CR29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood-2017-04-776740","volume":"130","author":"P Balsas","year":"2017","unstructured":"Balsas P, Palomero J, Eguileor A, et al. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood. 2017;130:501\u201313.","journal-title":"Blood."},{"key":"681_CR30","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","volume":"113","author":"AV Kurtova","year":"2009","unstructured":"Kurtova AV, Tamayo AT, Ford RJ, et al. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113:4604\u201313.","journal-title":"Blood."},{"key":"681_CR31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/RLU.0000000000002166","volume":"43","author":"S Kuyumcu","year":"2018","unstructured":"Kuyumcu S, Yilmaz E, Buyukkaya F, et al. Imaging of chemokine receptor CXCR4 in mycosis fungoides using 68Ga-Pentixafor PET\/CT. Clin Nucl Med. 2018;43:606\u20138.","journal-title":"Clin Nucl Med"},{"key":"681_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1309\/RF4PVCEGGN2XAF86","volume":"119","author":"AP Weng","year":"2003","unstructured":"Weng AP, Shahsafaei A, Dorfman DM. CXCR4\/CD184 immunoreactivity in T-cell non-Hodgkin lymphomas with an overall Th1- Th2+ immunophenotype. Am J Clin Pathol. 2003;119:424\u201330.","journal-title":"Am J Clin Pathol"},{"key":"681_CR33","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1080\/10428190410001723449","volume":"45","author":"S Wong","year":"2004","unstructured":"Wong S, Fulcher D. Chemokine receptor expression in B-cell lymphoproliferative disorders. Leuk Lymphoma. 2004;45:2491\u20136.","journal-title":"Leuk Lymphoma"},{"key":"681_CR34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1182\/blood-2003-09-3103","volume":"104","author":"L Trentin","year":"2004","unstructured":"Trentin L, Cabrelle A, Facco M, et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood. 2004;104:502\u20138.","journal-title":"Blood."},{"key":"681_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.5114\/pdia.2015.48034","volume":"32","author":"J Maj","year":"2015","unstructured":"Maj J, Jankowska-Konsur AM, Halon A, et al. Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides. Postepy Dermatol Alergol. 2015;32:437\u201342.","journal-title":"Postepy Dermatol Alergol"},{"key":"681_CR36","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjd.13054","volume":"171","author":"RN Daggett","year":"2014","unstructured":"Daggett RN, Kurata M, Abe S, et al. Expression dynamics of CXCL12 and CXCR4 during the progression of mycosis fungoides. Br J Dermatol. 2014;171:722\u201331.","journal-title":"Br J Dermatol"},{"key":"681_CR37","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1182\/blood-2005-04-1492","volume":"107","author":"MG Narducci","year":"2006","unstructured":"Narducci MG, Scala E, Bresin A, et al. Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26\/dipeptidylpeptidase IV. Blood. 2006;107:1108\u201315.","journal-title":"Blood."},{"key":"681_CR38","first-page":"838","volume":"45","author":"ZZ Yu","year":"2016","unstructured":"Yu ZZ, Xi YF, Li J, et al. Significance of CXCL12\/CXCR4 expression in T-lymphoblastic lymphoma\/leukemia. Zhonghua Bing Li Xue Za Zhi. 2016;45:838\u201343.","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"681_CR39","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2169\/internalmedicine.47.0500","volume":"47","author":"H Makishima","year":"2008","unstructured":"Makishima H, Komiyama Y, Asano N, et al. Peripheral T-cell lymphoma following diffuse large B-cell lymphoma associated with celiac disease. Intern Med. 2008;47:295\u20138.","journal-title":"Intern Med"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-020-00681-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-020-00681-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-020-00681-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T20:21:11Z","timestamp":1628108471000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-020-00681-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["681"],"URL":"https:\/\/doi.org\/10.1186\/s13550-020-00681-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-34553\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-34553\/v1","asserted-by":"object"}]},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,5]]},"assertion":[{"value":"9 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We performed this study in compliance with the 1964 Helsinki Declaration and its later amendments and federal laws in China. The study was approved by the institutional review board of PUMCH (IRB protocol #ZS-1113) and registered at\n                      \n                      (NCT 03436342). All patients signed written informed consent for participation in this study, and written informed consent of legal representative of the patients under 18 years old was also obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients signed written informed consent for the use of their data in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}